Navigation Links
Midwest is cost-effective for startup biotech companies

In May 2003, I wrote a column about the cost of doing business (CODB) for biotech companies in different parts of the United States. The point of the column was that one of the advantages of doing business in the Midwest is a significant cost advantage versus setting up shop in other parts of the country (or even the world).

We know that the cost of wet lab ......

Full article >>> of the biotech industry.

I will warn you in advance that I'm not going to include all 50 cities. Instead, I'm giving you a sampling of cities.

In all fairness to the European cities listed here, part of their high cost is the increased valuation of the Euro against the U.S. dollar. The U.S. dollar is currently worth about 80 percent of one Euro. The value of the Euro has increase......

Full article >>> raise more money may outweigh the higher CODB. San Diego is probably the most cost-effective place as the CODB is about the same as Chicago but with a greater ability to raise VC funds. In the Midwest, Minneapolis is clearly king when you factor in CODB and ability to raise VC money.

When I started this column back in February 2003, I did so under the firm belief that no individual was c......

Full article >>> or opinions expressed herein.......

Full article >>>
'"/>

Source:wistechnology.com By Michael Rosen 02/21/05


Related biology technology :

1. Midwest life science stocks kept sizzling in Q2
2. Midwest life science stocks sizzle in a tepid first quarter
3. A Midwest passage to India, Part II
4. Midwest offers non-stop flight to North Carolina research park
5. A Midwest life-science odyssey comes full circle
6. Midwest hotter for healthcare investments
7. A Midwest small-cap, life-science surprise package
8. 2006: A mixed blessing for Midwest life science companies
9. Midwest gaining stature in nanotech research
10. Midwest colleges strong contenders for NIH funds
11. Japan on the rebound: Implications for Midwest
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... , March 24, 2017  Infectex Ltd., a ... today announced positive results of a Phase 2b-3 clinical ... regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 ... at Sequella, Inc. ( USA ) and ... A total of 140 patients were enrolled in a ...
(Date:3/24/2017)... March 24, 2017 Agenus Inc. (NASDAQ: AGEN), ... antibodies and cancer vaccines, today announced participation at the ...  Annual William Blair and Maidstone Life Sciences conference "Cancer ... in New York, NY . Agenus ... 29 at 9:40 am: Robert B. Stein , ...
(Date:3/23/2017)... , March 23, 2017  SeraCare ... to global in vitro diagnostics manufacturers and ... the industry,s first multiplexed Inherited Cancer ... testing by next-generation sequencing (NGS). The Seraseq™ ... developed with input from industry experts to ...
(Date:3/23/2017)... NetworkNewsWire Editorial Coverage  ... Cancer remains one of the world,s ... systems, in terms of costs and resources. However, as the ... of innovative and efficient therapies that demonstrate higher chances of ... cancer treatments, a growing number of patients receiving immuno-oncology therapies ...
Breaking Biology Technology:
(Date:2/24/2017)... -- EyeLock LLC, a leader of iris-based identity authentication ... solution on the latest Qualcomm® Snapdragon™ 835 mobile ... Congress 2017 (February 27 – March 2, ... Stand 3E10. The Snapdragon 835 ... combination of hardware, software and biometrics technologies ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
Breaking Biology News(10 mins):